Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.70 |
| ▸ | THRB | P10828 | 1/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.70 |
| ▸ | CA2 | P00918 | 7/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.56 |
| ▸ | FYN | P06241 | 1/20 | 0.56 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.56 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.56 |
| ▸ | DRD4 | P21917 | 1/20 | 0.56 |
| ▸ | DRD3 | P35462 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 6/20 | 0.55 |
| ▸ | CA1 | P00915 | 5/20 | 0.55 |
| ▸ | CA9 | Q16790 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | CA4 | P22748 | 2/20 | 0.51 |
| ▸ | CA5A | P35218 | 2/20 | 0.51 |
| ▸ | CA7 | P43166 | 2/20 | 0.51 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL77518 | 1.00 | CYP2D6 (0.70) | CYP2D6THRBHSD17B10CA2TSHR | |
| SCHEMBL17327517 | 1.00 | CYP2D6 (0.70) | CYP2D6THRBHSD17B10CA2TSHR | |
| SCHEMBL19735717 | 1.00 | CYP2D6 (0.70) | CYP2D6THRBHSD17B10CA2TSHR | |
| SCHEMBL5410915 | 1.00 | CYP2D6 (0.70) | CYP2D6THRBHSD17B10CA2TSHR | |
| SCHEMBL24584612 | 1.00 | CYP2D6 (0.70) | CYP2D6THRBHSD17B10CA2TSHR | |
| SCHEMBL20524278 | 1.00 | CYP2D6 (0.70) | CYP2D6THRBHSD17B10CA2TSHR | |
| SCHEMBL23330709 | 1.00 | CYP2D6 (0.70) | CYP2D6THRBHSD17B10CA2TSHR | |
| SCHEMBL258821 | 1.00 | CYP2D6 (0.70) | CYP2D6THRBHSD17B10CA2TSHR | |
| SCHEMBL502378 | 1.00 | CYP2D6 (0.70) | CYP2D6THRBHSD17B10CA2TSHR | |
| SCHEMBL13396023 | 1.00 | CYP2D6 (0.70) | CYP2D6THRBHSD17B10CA2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2003002586-A1 | [4-(4-CYANOBENZOYL)PHENYL]GLYCOFURANOSIDE DERIVATIVES, USE OF SAID DERIVATIVES AS A MEDICAMENT, PRODUCTION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | LABORATOIRES FOURNIER SA (FR) | 2003-01-09 | — | — | WO | claimed |
| JP-1319496-A | — | — | None | — | — | JP | disclosed |
| CN-110291095-B | Adenosine analogues and their use in regulating circadian clock | 北京生命科学研究所 | 2023-04-18 | — | — | CN | disclosed |
| US-20210338706-A1 | ADENOSINE ANALOG AND ITS USE IN REGULATING THE CIRCADIAN CLOCK | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2021-11-04 | — | — | US | disclosed |
| US-9062088-B2 | CDK-inhibiting pyrrolopyrimidine carboxamide derivative or pharmaceutically acceptable salt thereof, and pharmaceutical composition containing the same as active ingredient for preventing or treating hepatocellular carcinoma | SNU R&DB FOUNDATION (KR) | 2015-06-23 | — | — | US | disclosed |
| US-20130237495-A1 | CDK-INHIBITING PYRROLOPYRIMIDINONE CARBOXAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING HEPATOCELLULAR CARCINOMA | SNU R&DB FOUNDATION (KR) | 2013-09-12 | — | — | US | disclosed |
| EP-2636677-A1 | CDK-INHIBITING PYRROLOPYRIMIDINONE CARBOXAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING LIVER CELL CANCER | SNU R & DB Foundation (KR) | 2013-09-11 | — | — | EP | disclosed |
| US-8389565-B2 | Antidiabetic agents; controlling carbohydrate metabolism | SIMON FRASER UNIVERSITY (CA) | 2013-03-05 | — | — | US | disclosed |
| WO-2012060482-A1 | CDK-INHIBITING PYRROLOPYRIMIDINONE CARBOXAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING LIVER CELL CANCER | 서울대학교 산학협력단 (KR) | 2012-05-10 | — | — | WO | disclosed |
| US-20090048203-A1 | SUBSTITUTED ADENINES AND THE USES THEREOF | ASTRAZENECA AB (SE) | 2009-02-19 | — | — | US | disclosed |
| US-5599796-A | USING BORON CLUSTER-CONTAINING NUCLEOSIDES OR OLIGONUCLEOTIDES; PARTICULARLY EFFECTIVE FOR BLADDER, PROSTATE AND KIDNEY | EMORY UNIVERSITY (US) | 1997-02-04 | — | — | US | disclosed |
| US-5596087-A | Process for the preparation of beta thymidine | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 1997-01-21 | — | — | US | disclosed |
| EP-0683171-A1 | A process for the preparation of beta-thymidine | Council of Scientific and Industrial Research (IN) | 1995-11-22 | — | — | EP | disclosed |
| EP-0348446-B1 | ANTIVIRAL ANTITUMOR ANTIMETASTATIC IMMUNE SYSTEM ENHANCING NUCLEOSIDES AND NUCLEOTIDES | UNIV BRIGHAM YOUNG (US) | 1995-08-09 | — | — | EP | disclosed |
| EP-0636372-A1 | Antiviral, antitumor, antimetastatic, immune system enhancing 7-thia-guanosine derivatives | BRIGHAM YOUNG UNIVERSITY (US) | 1995-02-01 | — | — | EP | disclosed |
| EP-0348446-A4 | ANTIVIRAL ANTITUMOR ANTIMETASTATIC IMMUNE SYSTEM ENHANCING NUCLEOSIDES AND NUCLEOTIDES | — | 1991-09-25 | — | — | EP | disclosed |
| US-5041426-A | Viricides, antitumor agents | BRIGHAM YOUNG UNIVERSITY (US) | 1991-08-20 | — | — | US | disclosed |
| EP-0348446-A1 | ANTIVIRAL ANTITUMOR ANTIMETASTATIC IMMUNE SYSTEM ENHANCING NUCLEOSIDES AND NUCLEOTIDES. | UNIV BRIGHAM YOUNG (US) | 1990-01-03 | — | — | EP | disclosed |
| JP-H01319496-A | URACIL DERIVATIVE | T HASEGAWA CO LTD | 1989-12-25 | — | — | JP | disclosed |
| WO-1989005649-A1 | ANTIVIRAL ANTITUMOR ANTIMETASTATIC IMMUNE SYSTEM ENHANCING NUCLEOSIDES AND NUCLEOTIDES | BRIGHAM YOUNG UNIVERSITY (US) | 1989-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048203-A1 | SUBSTITUTED ADENINES AND THE USES THEREOF | HPRT1, APRT, NUDT1 | CYP2D6 301/4885THRB 3402/4885HSD17B10 1880/4885 |
| US-20130237495-A1 | CDK-INHIBITING PYRROLOPYRIMIDINONE CARBOXAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING HEPATOCELLULAR CARCINOMA | CDK7, CDK4, CDK14 | CYP2D6 2324/4885THRB 4725/4885HSD17B10 2634/4885 |
| US-20210338706-A1 | ADENOSINE ANALOG AND ITS USE IN REGULATING THE CIRCADIAN CLOCK | PER2, CRY1, ADORA2A | CYP2D6 3612/4885THRB 1199/4885HSD17B10 3429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.